PRESS RELEASE published on 05/17/2023 at 12:30, 2 years 6 months ago Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis
PRESS RELEASE published on 05/06/2023 at 12:30, 2 years 6 months ago Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action
PRESS RELEASE published on 05/04/2023 at 12:30, 2 years 7 months ago Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders
PRESS RELEASE published on 04/27/2023 at 12:30, 2 years 7 months ago Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.
PRESS RELEASE published on 04/26/2023 at 12:30, 2 years 7 months ago Immunic to Participate in Investor and Scientific Conferences in May
PRESS RELEASE published on 04/05/2023 at 12:30, 2 years 7 months ago Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis
PRESS RELEASE published on 03/02/2023 at 12:30, 2 years 9 months ago Immunic to Participate in Investor and Scientific Conferences in March
PRESS RELEASE published on 02/22/2023 at 12:30, 2 years 9 months ago Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023
PRESS RELEASE published on 02/09/2023 at 12:30, 2 years 9 months ago Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need
PRESS RELEASE published on 01/25/2023 at 12:30, 2 years 10 months ago Immunic to Participate in Scientific and Investor Conferences in February
Published on 12/05/2025 at 02:35, 5 hours 11 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 6 hours 46 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 41 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 46 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 45 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 4 hours 15 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 55 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 11 hours 20 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 31 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:00, 13 hours 46 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 14 hours 1 minute ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 14 hours 1 minute ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 13 hours ago Declaration of voting rights at the end of November 2025
